pharmaceutical intermediates
the so-called pharmaceutical intermediates are actually some chemical raw materials or chemical products used in the process of drug synthesis. this chemical product does not require a production license for drugs, it can be produced in ordinary chemical plants, and can be used in the synthesis of drugs as long as it reaches some levels.
chinese name: pharmaceutical intermediates
explanation: some chemicals used in drug synthesis
purpose: synthesis of drugs
characteristics: the profit margin of production intermediates is low
representatives: fluoropridines, etc
field: medicine
directory
1 introduction
overview
demand increases
2. pharmaceutical machinery exhibition
contains fluoropridine
the gap is large
3. features
review
peculiarity
4. related introduction
fluoropridine-containing intermediates became hot spots
the p-aminopheran gap is large
5. analysis of the current situation of the industry
the trajectory comes from medicine to medicine
basic conditions are still restricting development
the continuity of regular technology development determines the number of enterprises
brief introduction
overview
our country needs more than 2,000 kinds of raw materials and intermediates supporting chemical industry every year, with a demand of more than 2.5 million tons. after more than 30 years of development, the chemical raw materials and intermediates required for pharmaceutical production in our country can basically be matched, and only a small part needs to be imported. and because our country is relatively rich in resources and the price of raw materials is low, many intermediates have achieved a large number of exports. so, what development opportunities does our country’s pharmaceutical intermediates field face?
demand increases
our country β-lactam antibiotics have formed a complete production system after nearly 50 years of development. in 2012, almost all β-lactam antibiotics (except for varieties within the patent period) our country can be produced, and the cost is very low, and the production of penicillin ranks among the top in the world, and a large number of exports are supplied to the international market; cephalosporin antibiotics are basically self-sufficient and can still strive for some exports.
in 2012, all intermediates our country matched with β-lactam antibiotics can be produced by themselves, except for the parent core 7-aca and 7-adca of semi-synthetic antibiotics, which need to be partially imported, all side-chain intermediates can be produced and exported in large quantities.
taking phenylacetic acid, the main supporting intermediate of β-lactam antibiotics, as an example, there are nearly 30 phenylacetic acid manufacturers our country the existing phenylacetic acid, with a total annual production capacity of about 20,000 tons. however, most enterprises are small, with an annual output of 2,000 tons for large ones and hundreds of tons for other large years. in 2003, the total demand for phenylacetic acid in china was about 14,000 tons, and the consumption structure was: penicillin g accounted for 85%, other medicines accounted for 4%, fragrances accounted for 7%, and pesticides and other fields accounted for 4%.
with the development of domestic fragrance, medicine, pesticide and other industries, the demand for phenylacetic acid will further increase. it is expected that by 2005, our country’s pharmaceutical industry will consume about 14,000 tons of phenylacetic acid, the pesticide industry will consume 500 tons, and the fragrance industry will consume about 2,000 tons. combined with the consumption in other fields, it is expected that the total domestic demand for phenylacetic acid will reach 18,000 tons in 2005.
contains fluoropridine
fluoropridine-containing intermediates became hot spots
as of 2012, the quinolone antibacterial drugs that have been developed and put into mass production in our country mainly include norfloxacin, ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, flurofloxacin, etc. among them, norfloxacin, ciprofloxacin and ofloxacin are produced in large quantities, accounting for about 98% of the total production of fluoroquinolone antibacterial drugs in china.
quinolones are generally obtained by synthesizing fluoroquinolines from fluorinated benzene rings and condensing them with piperazine (or methylpiperazine). due to our country’s abundant fluorite reserves, it is one of the countries with a large production of fluorine-containing drugs and intermediates in the world, and more than 80% of fluorine-containing intermediates are supplied for export. on the whole, our country’s fluorobenzene intermediates developed earlier, and the production capacity was generally overcapacity. trifluorotoluene intermediates developed late and developed rapidly; for heterocyclic aromatic compounds, especially fluoropridine-containing compounds, only a few research units and manufacturers in our country have the synthesis technology of fluoropridine-containing intermediates, so fluoropridine-containing intermediates will become one of the main directions of domestic fluorointermediate research and development in the next few years.
the gap is large
our country has become the world’s largest producer of antipyretic and analgesic drugs, with an output of more than 10,000 tons of aspirin, paracetamol, analgine and other varieties, and more than 1,000 tons of phenaxetine, aminopyrine, antepyrine and other varieties. at present, the production of antipyretic and analgesic drugs in our country is growing rapidly, and it is expected to grow at a rate of about 8% in the future. the production of intermediates for antipyretic and analgesic drugs is large, and there are many manufacturers. with the growth of antipyretic and analgesic drugs, its intermediates have also made great progress.
in 2003, domestic paracetamol consumption increased rapidly, and exports also showed a rapid growth momentum, with an export volume of 28,163 tons, an annual export volume of about 1 times year-on-year. by the first half of 2004, although its export growth rate slowed n, it still increased, and the export volume of paracetamol in january ~ may 2004 was 12,501 tons, slightly higher than the same period last year. p-aminophen is an important intermediate in the synthesis of paracetamol and grows rapidly. our country’s annual output of aminophenol is 32,000 tons, it is expected that by 2005, the domestic paracetamol output will reach more than 50,000 tons, the pharmaceutical industry will consume 45,000 tons of p-aminophenol, coupled with the application in other fields, the total demand for aminophenol in 2005 is about 50,000 tons, the market gap is large, and the development and utilization prospects are broad.
peculiarity
review
looking at the entire industry, there are six characteristics of pharmaceutical intermediate production in our country:
peculiarity
first, most of the production enterprises are private enterprises, with flexible operation and small investment scale, basically between millions and 10 million yuan; second, the geographical distribution of production enterprises is relatively concentrated, mainly distributed in the areas centered on taizhou, zhejiang and jintan, jiangsu; third, with the increasing attention of the state to environmental protection issues, the pressure on production enterprises to build environmental protection treatment facilities has increased; fourth, the product update speed is fast. a product generally has a profit margin drop significantly after 3~5 years on the market, which forces enterprises to continuously develop new products or continuously improve production processes in order to maintain high production profits; fifth, because the production profit of pharmaceutical intermediates is higher than that of chemical products, and the production process of the two is basically the same, more and more small chemical enterprises have joined the ranks of producing pharmaceutical intermediates, resulting in increasingly fierce competition in the industry. sixth, compared with apis, the profit margin of production intermediates is low, and the production process of apis and pharmaceutical intermediates is similar, so some enterprises have not only produced intermediates, but also used their own advantages to start producing apis.
related introduction
fluoropridine-containing intermediates became hot spots
at present, the quinolone antibacterial drugs that have been developed and put into mass production in our country mainly include norfloxacin, ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, flurofloxacin, etc. among them, norfloxacin, ciprofloxacin and ofloxacin are produced in large quantities, accounting for about 98% of the total output of fluoroquinolone antimicrobials in china.
quinolones are generally obtained by synthesizing fluoroquinolines from fluorinated phenyl rings and then condensing with piperazine (or methylpiperazine). due to our country’s abundant fluorite reserves, it is one of the countries with a large production of fluorine-containing drugs and intermediates in the world, and more than 80% of fluorine-containing intermediates are supplied for export. on the whole, fluorobenzene intermediates in our country developed earlier, and the current production capacity is generally overcapacity; trifluorotoluene intermediates developed late and developed rapidly in recent years; for heterocyclic aromatic compounds, especially fluoropridines, only a few research units and manufacturers in our country have the synthesis technology of fluoropridine-containing intermediates, so fluoropridine-containing intermediates will become one of the main directions of domestic fluorinated intermediate research and development in the next few years.
the p-aminopheran gap is large
our country has become the world’s largest producer of antipyretic and analgesic drugs, with an output of more than 10,000 tons of aspirin, paracetamol, analgine and other varieties, and more than 1,000 tons of phenaxetine, aminopyrine, antepyrine and other varieties. at present, the production of antipyretic and analgesic drugs in our country is growing rapidly, and it is expected to grow at a rate of about 8% in the future. the production of intermediates for antipyretic and analgesic drugs is large, and there are many manufacturers. with the growth of antipyretic and analgesic drugs, its intermediates have also made great progress.
in 2003, domestic paracetamol consumption increased rapidly, and exports also showed a rapid growth momentum, with an export volume of 28,163 tons, an annual export volume of about 1 times year-on-year. by the first half of 2004, although its export growth rate slowed n, it still increased, and the export volume of paracetamol in january ~ may 2004 was 12,501 tons, slightly higher than the same period last year. p-aminophen is an important intermediate in the synthesis of paracetamol and has also grown rapidly in recent years. at present, our country’s annual output of aminophenol is about 32,000 tons, it is expected that by 2005, the domestic paracetamol output will reach more than 50,000 tons, the pharmaceutical industry will consume 45,000 tons of p-aminophel, coupled with the application in other fields, the total demand for aminophenol in 2005 is about 50,000 tons, the market gap is large, and the development and utilization prospects are broad.
analysis of the current situation of the industry
after the glory of the late 90s of the last century, the pharmaceutical intermediates industry has basically entered a mature stage, and the competition between enterprises has reached a white heat, and everyone is fighting for a little strength behind each other, whoever can persist until the latter is the survivor, and at the same time is tempted by various legends and other factors, and there are constantly new investors full of “gold panning” dream of entering the industry, however, with the rise of the state requiring pharmaceutical companies to carry out gmp certification and various overseas certifications, the scale of investment in the pharmaceutical industry has risen geometrically, how to make limited funds and energy produce large economic and social benefits, has become the goal pursued by every pharmaceutical intermediate investor
the trajectory comes from medicine to medicine
the impact of the process of economic globalization on our country’s economy is far-reaching, that is, each production enterprise does not need to be large and complete, should concentrate funds and energy on the industry and field it is good at, other supporting materials and conditions can be completed by social cooperation, through the formation of a product chain, so that both parties can achieve a win-win situation, under the influence of this concept, the pharmaceutical industry will transfer the processing of some primary products, such as solvent recycling and other work to cooperative enterprises, and then gradually transfer some polluting and dangerous products to chemical plants for production, such as penicillin, the use of phenylacetic acid chloroacetic acid has appeared in large quantities since the 7080s of the last century supporting small township enterprises and individual enterprises producing phenylacetic acid and chloroacetic acid for north china pharmaceutical
with the deepening of cooperation between the two sides, pharmaceutical companies have gradually transferred some products with high added value and technical difficulties to chemical plants, such as the production of cephalosporin antibiotics, such as amidiaxime acid, ae-active ester, triazine, cyclotetraazole, acetic acid, p-hydroxybenzglycine (potassium salt), ho- epcp and other products, which has led to the rapid development of this branch industry in the 90s of the last century, and has achieved a number of pharmaceutical intermediate enterprises with an output value of tens of millions to 100 million yuan, such as zhejiang yongning pharmaceutical factory, fushun mei compulsory pharmaceutical factory, zhejiang hengdian debang group, shandong ruiying group, shandong jincheng chemical plant and many other enterprises. and sell the products to pharmaceutical companies in the form of chemical products for refining and then sell them as drugs, the pharmaceutical intermediates industry can further extend the product chain, increase the profit of products and improve the stability of sales, while pharmaceutical companies reduce investment, and put limited funds and energy on aseptic packaging that they are good at, because the pharmaceutical intermediates industry does not have a production license for pharmaceutical products, it is impossible to compete with pharmaceutical companies for the market, so the cooperation between the two sides has certain complementary conditions, and the basic conditions are still restricting development
at present, domestic manufacturers of cephalosporin antibiotic parent nucleus 7-aca, including cspc pharmaceutical, fukang, lubang, etc., have completely reversed the situation of foreign 7-aca occupying the domestic market, and foreign manufacturers have withdrawn from the domestic market, resulting in the current domestic 7- the supply of aca is very tight, and the domestic cephalosporin antibiotic consumer market has matured, so it has driven the domestic cephalosporin antibiotic intermediates to be in short supply, such a situation will cause a new round of investment climax, but due to the above analysis of various reasons, it is difficult for new enterprises to compete with established enterprises, although some established enterprises have stopped the production of one or several varieties, but it is easy to resume production, so it is said that although there is a large space for development in the domestic cephalosporin antibiotic pharmaceutical intermediate market, there is considerable risk for new investors, due to the current increasingly hot cephalosporin antibiotic market, resulting in penicillins the price of antibiotic products is low, so it is also a good investment route to carry out penicillin modification to synthesize new antibiotics, such as melocillin, alocillin, piperacillin, etc., because of its good efficacy, low price, sufficient supply of raw materials, etc., have very good development prospects, and at the same time, the transformation of penicillin into the parent nucleus of cephalosporin antibiotics, such as 7-adcagclegeo, etc., is also a product investment with good market prospects, these products can avoid head-on conflict with mature and strong competitors, and can play a surprisingly winning